These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16248786)

  • 1. Cell cycle regulatory kinase modulators: interim progress and issues.
    Sausville EA
    Curr Top Med Chem; 2005; 5(12):1109-17. PubMed ID: 16248786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early development of cyclin dependent kinase modulators.
    Roy KK; Sausville EA
    Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule cyclin-dependent kinase modulators.
    Senderowicz AM
    Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.
    Senderowicz AM
    Oncologist; 2002; 7 Suppl 3():12-9. PubMed ID: 12165651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule modulators of cyclin-dependent kinases for cancer therapy.
    Senderowicz AM
    Oncogene; 2000 Dec; 19(56):6600-6. PubMed ID: 11426645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
    Akiyama T; Sugiyama K; Shimizu M; Tamaoki T; Akinaga S
    Jpn J Cancer Res; 1999 Dec; 90(12):1364-72. PubMed ID: 10665655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
    Raju U; Nakata E; Mason KA; Ang KK; Milas L
    Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
    Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
    J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
    Fischer PM; Lane DP
    Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
    De Azevedo WF; Mueller-Dieckmann HJ; Schulze-Gahmen U; Worland PJ; Sausville E; Kim SH
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2735-40. PubMed ID: 8610110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATP-site directed inhibitors of cyclin-dependent kinases.
    Gray N; Détivaud L; Doerig C; Meijer L
    Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin.
    Wesierska-Gadek J; Gueorguieva M; Horky M
    Pol J Pharmacol; 2003; 55(5):895-902. PubMed ID: 14704484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of CDKs as a therapeutic modality.
    Sausville EA; Johnson J; Alley M; Zaharevitz D; Senderowicz AM
    Ann N Y Acad Sci; 2000 Jun; 910():207-21; discussion 221-2. PubMed ID: 10911915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and clinical development of cyclin-dependent kinase modulators.
    Senderowicz AM; Sausville EA
    J Natl Cancer Inst; 2000 Mar; 92(5):376-87. PubMed ID: 10699068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
    Zaharevitz DW; Gussio R; Leost M; Senderowicz AM; Lahusen T; Kunick C; Meijer L; Sausville EA
    Cancer Res; 1999 Jun; 59(11):2566-9. PubMed ID: 10363974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle modulators for the treatment of lung malignancies.
    Senderowicz AM
    Clin Lung Cancer; 2003 Nov; 5(3):158-68. PubMed ID: 14667271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Regulation of the cell cycle--involvement of protein inhibitors of cyclin-dependent kinases].
    Grzelakowska-Sztabert B
    Postepy Biochem; 1995; 41(2):80-93. PubMed ID: 7479444
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.